Search Results - "Caitlyn McCarthy"

Effectiveness of double-dose dolutegravir in people receiving rifampin-based tuberculosis treatment: an observational, cohort study of people with HIV from six countries by Shah, N Sarita, Kityo, Cissy, Hughes, Michael D, McCarthy, Caitlyn, Wallis, Carole, Hosseinipour, Mina, Langat, Deborah, Nyirenda, Mulinda, Rassool, Mohammed, Dawson, Rodney, Joseph, Yvetot, Some, Fatma, Mngqbisa, Rosie, Mukwekwerere, Pamela Grace, Woolley, Elizabeth, Godfrey, Catherine, Manabe, Yukari C, Mellors, John W, Flexner, Charles, Maartens, Gary

“…Tenofovir-lamivudine-dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen. An additional 50 mg dose of dolutegravir (TLD + 50)…”
Get full text

Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With Human Immunodeficiency Virus From 6 Countries by Shah, N Sarita, Kityo, Cissy, Hughes, Michael D, McCarthy, Caitlyn, Wallis, Carole L, Hosseinipour, Mina C, Langat, Deborah, Nyirenda, Mulinda, Rassool, Mohammed, Dawson, Rodney, Joseph, Yvetot, Some, Fatma, Mngqibisa, Rosie, Mukwekwerere, Pamela Grace, Woolley, Elizabeth, Godfrey, Catherine, Manabe, Yukari C, Mellors, John W, Flexner, Charles, Maartens, Gary, Jezile, Vuyokazi S, Mwelase, Thando, Louis, Marie Jude Jean, François, Daphie Jean, Siika, Abraham, Kirui, Viola, Madlala, Penelope, Casey, Petronella, Samaneka, Wadzanai, Musodza, Yeukai, Magengo, Nadia, Moonsamy, Suri

“…Abstract Background Tenofovir-lamivudine-dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen. An additional 50-mg dose of…”
Get full text

Third‐line antiretroviral therapy, including raltegravir , is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial by Avihingsanon, Anchalee, Hughes, Michael D, Salata, Robert, Godfrey, Catherine, Mccarthy, Caitlyn, Mugyenyi, Peter, Hogg, Evelyn, Gross, Robert, Cardoso, Sandra W, Bukuru, Aggrey, Makanga, Mumbi, Badal?Aesen, Sharlaa, Mave, Vidya, Ndege, Beatrice Wangari, Fontain, Sandy Nerette, Samaneka, Wadzanai, Secours, Rode, Van Schalkwyk, Marije, Mngqibisa, Rosie, Mohapi, Lerato, Valencia, Javier, Sugandhavesa, Patcharaphan, Montalban, Esmelda, Munyanga, Cornelius, Chagomerana, Maganizo, Santos, Breno R, Kumarasamy, Nagalingeswaran, Kanyama, Cecilia, Schooley, Robert T, Mellors, John W, Wallis, Carole L, Collier, Ann C, Grinsztejn, Beatriz

“…Introduction: ACTG A5288 was a strategy trial conducted in diverse populations from multiple continents of people living with HIV (PLWH) failing second‐line…”
Get full text

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial by Avihingsanon, Anchalee, Hughes, Michael D., Salata, Robert, Godfrey, Catherine, McCarthy, Caitlyn, Mugyenyi, Peter, Hogg, Evelyn, Gross, Robert, Cardoso, Sandra W., Bukuru, Aggrey, Makanga, Mumbi, Badal‐aesen, Sharlaa, Mave, Vidya, Ndege, Beatrice Wangari, Fontain, Sandy Nerette, Samaneka, Wadzanai, Secours, Rode, Van Schalkwyk, Marije, Mngqibisa, Rosie, Mohapi, Lerato, Valencia, Javier, Sugandhavesa, Patcharaphan, Montalban, Esmelda, Munyanga, Cornelius, Chagomerana, Maganizo, Santos, Breno R., Kumarasamy, Nagalingeswaran, Kanyama, Cecilia, Schooley, Robert T., Mellors, John W., Wallis, Carole L., Collier, Ann C., Grinsztejn, Beatriz

“…Introduction ACTG A5288 was a strategy trial conducted in diverse populations from multiple continents of people living with HIV (PLWH) failing second‐line…”
Get full text

Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial by Jagannathan, Prasanna, Giganti, Mark J., Hughes, Michael D., Moser, Carlee, Main, Mark J., Monk, Phillip D., Javan, Arzhang Cyrus, Fletcher, Courtney V., McCarthy, Caitlyn, Wohl, David A., Daar, Eric S., Eron, Joseph J., Singh, Upinder, Smith, Davey M., Fischer, William, Chew, Kara, Smith, David (Davey), Daar, Eric, Wohl, David, Currier, Judith, Eron, Joseph, Javan, Arzhang Cyrus, Moser, Carlee, Giganti, Mark, Hosey, Lara, Roa, Jhoanna, Patel, Nilam, Colsh, Kelly, Rwakazina, Irene, Sieg, Scott, Li, Jonathan, Fletcher, Courtney, Fischer, William, Evering, Teresa, Ignacio, Rachel Bender, Cardoso, Sandra, Corado, Katya, Jagannathan, Prasanna, Jilg, Nikolaus, Perelson, Alan, Pillay, Sandy, Riviere, Cynthia, Singh, Upinder, Taiwo, Babafemi, Gottesman, Joan, Newell, Matthew, Pedersen, Susan, Dragavon, Joan, Jennings, Cheryl, Greenfelder, Brian, Murtaugh, William, Gapara, Morgan, Shahkolahi, Akbar, Main, Mark J., Pierone, Gerald, Elliott, Juliana, Jacobson, Jeffrey, Hojat, Leila, Pasternak, Julie, Berardi, Jonathan, Arar, Celine, Bukhman, Yevgeniy, Jain, Manish, Bukhman, Eugene, Shaik, Sadia, Hatlen, Timothy, Dooley, Kelly, Wilkins, Adaliah, Pérez, Jose, Fernández, Heriberto, Hoover, Keila, Renfroe, James, Weldon, Mauney, Bougher, Genei, Malvestutto, Carlos, Harber, Heather, Cicarella, Robyn, Neytman, Gene, Herman, Jack, Herman, Craig, Swiatek, Joan, Pathak, Divya, Choudhary, Madhu, Sullivano, Jennifer, Torna, Odelsey, Khodabakhshian, Aleen, Benson, Constance, Hendrickx, Steven, Luetkemeyer, Anne, Dentoni-Lasofsky, Dennis, Spikes, Leslie, Hall, Chase, Oakes, Jonathan, Loftis, Amy James, Tebas, Pablo, Short, William, McGuffin, Sarah, Jonsson, Chris, Presti, Rachel, Haile, Alem

“…With the emergence of SARS-CoV-2 variants resistant to monoclonal antibody therapies and limited global access to therapeutics, the evaluation of novel…”
Get full text

Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trialResearch in context by Prasanna Jagannathan, Kara W. Chew, Mark J. Giganti, Michael D. Hughes, Carlee Moser, Mark J. Main, Phillip D. Monk, Arzhang Cyrus Javan, Jonathan Z. Li, Courtney V. Fletcher, Caitlyn McCarthy, David A. Wohl, Eric S. Daar, Joseph J. Eron, Judith S. Currier, Upinder Singh, Davey M. Smith, William Fischer, Kara Chew, David (Davey) Smith, Eric Daar, David Wohl, Judith Currier, Joseph Eron, Arzhang Cyrus Javan, Michael Hughes, Carlee Moser, Mark Giganti, Justin Ritz, Lara Hosey, Jhoanna Roa, Nilam Patel, Kelly Colsh, Irene Rwakazina, Justine Beck, Scott Sieg, Jonathan Li, Courtney Fletcher, William Fischer, Teresa Evering, Rachel Bender Ignacio, Sandra Cardoso, Katya Corado, Prasanna Jagannathan, Nikolaus Jilg, Alan Perelson, Sandy Pillay, Cynthia Riviere, Upinder Singh, Babafemi Taiwo, Joan Gottesman, Matthew Newell, Susan Pedersen, Joan Dragavon, Cheryl Jennings, Brian Greenfelder, William Murtaugh, Jan Kosmyna, Morgan Gapara, Akbar Shahkolahi, Mark J. Main, Gerald Pierone, Juliana Elliott, Jeffrey Jacobson, Leila Hojat, Julie Pasternak, Jonathan Berardi, Celine Arar, Yevgeniy Bukhman, Manish Jain, Eugene Bukhman, Sadia Shaik, Timothy Hatlen, Kelly Dooley, Becky Becker, Adaliah Wilkins, Jose Pérez, Eloy Roman, Heriberto Fernández, Keila Hoover, James Renfroe, Mauney Weldon, Genei Bougher, Carlos Malvestutto, Heather Harber, Robyn Cicarella, Gene Neytman, Jack Herman, Craig Herman, Mariam Aziz, Joan Swiatek, Divya Pathak, Madhu Choudhary, Jennifer Sullivano, Olayemi Osiyemi, Myriam Izquierdo, Odelsey Torna, Aleen Khodabakhshian, Samantha Fortier, Constance Benson

“…Background: With the emergence of SARS-CoV-2 variants resistant to monoclonal antibody therapies and limited global access to therapeutics, the evaluation of…”
Get full text

Are federal agencies the sole judges of their own authority? by Shapiro, Ilya, McCarthy, Caitlyn W

“…It is no secret that federal agencies incrementally expand their regulatory power by adopting statutory interpretations that go beyond the underlying…”
Get full text

Abstract 351: Optimizing the Frequency of Surveillance Echocardiography in Clinically Stable Patients With Hypertrophic Cardiomyopathy by Carr, Christina W, Conner, Lauren M, McCarthy, Caitlyn A, Greenberg, Jeffrey O, Laskowski, Karl R, Parambi, Ron J, Graham, Dionne A, Szent-Gyorgyi, Lara E, Cirino, Allison L, Ho, Carolyn Y, MacRae, Calum A, Seidman, Christine E, Ghazinouri, Roya, Lakdawala, Neal K

“…Abstract only Background: Hypertrophic cardiomyopathy (HCM) affects 0.2% of the population and is an important cause of sudden cardiac death, heart failure and…”
Get full text